"Treatment"

If you are suffering from itchy hair and hair loss, it is important to understand the causes of itchy hair and hair loss so that you can get to the root of the problem. For example, some people only have mild hair loss, which can be relieved after certain adjustments, while others have both itchy symptoms and hair loss symptoms that are more pronounced, so it is also important to pay attention to the right treatment

The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.

With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.

Osteoporosis is the cause of menopausal fractures! Do these 5 things to avoid osteoporosis

In recommendations released on 2 February 2023, the National Comprehensive Cancer Network (NCCN) recommends that doctors consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of their estrogen receptor status.

Prior to the granting of marketing authorisation by the MHRA, Biyze® had been approved by the European Commission for a number of indications and is currently the only drug approved for the treatment of MZL in Great Britain.

Oesophageal cancer is a disease that causes a series of symptoms in our body, and it can be said to be a disease that seriously affects our health.

Pancreatic cancer is a very complex and common tumour of the pancreas, and the malignancy of this disease is relatively high.

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!

According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.